Advances in intravitreal ganciclovir treatment of cytomegalovirus retinitis after hematopoietic stem cell transplantation
10.3760/cma.j.cn115989-20220116-00020
- VernacularTitle:更昔洛韦玻璃体腔注射治疗HSCT术后并发巨细胞病毒性视网膜炎研究进展
- Author:
Weibin CHEN
1
;
Mingwei ZHAO
;
Heng MIAO
Author Information
1. 北京大学人民医院眼科 北京大学人民医院眼视光中心 北京大学人民医院眼病与视光医学研究所 视网膜脉络膜疾病诊治研究北京市重点实验室 北京大学医学部眼视光学院，北京 100044
- Keywords:
Hematopoietic stem cell transplantation;
Cytomegalovirus retinitis;
Ganciclovir;
Intravitreal injections;
Clinical protocols
- From:
Chinese Journal of Experimental Ophthalmology
2023;41(10):1033-1037
- CountryChina
- Language:Chinese
-
Abstract:
Hematopoietic stem cell transplantation (HSCT) brings the possibility to prolong survival for patients with different types of hematological diseases, but patients may be complicated with cytomegalovirus retinitis (CMVR) due to immunocompromised state.Intravitreous injection of ganciclovir (IVG) is a major treatment in CMVR after HSCT, but there are significant differences in the dosage and frequency among existing IVG protocols due to lack of standardized consensus or guidelines.High-dose IVG therapy and a follow-up plan based on aqueous humor virus load and cytokine monitoring have been applied in clinical practice, and it has been reported to shorten treatment duration and reduce number of injections.Reports of retinal toxicity caused by IVG are rare, and more exploration is needed to determine the safe dose range of IVG.This article reviewed the advances in IVG treatment of CMVR after HSCT focusing on the acting mechanism of ganciclovir, the problems in systematic application, the treatment plan involving intravitreal injection, and the retinal toxicity of intravitreal injection.
